Had previously guided for FY25 Ingrezza net product sales of $2.5B-$2.6B. FY25 revenue consensus $2.69B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine reports Q2 non-GAAP EPS $1.65, consensus $1.50
- Neurocrine Biosciences Advances Schizophrenia Treatment with New Phase 3 Study
- These 3 Stocks are Screaming ‘Strong Buy,’ According to the Technical Analysis
- Strong Market Position and Growth Potential for Neurocrine’s Ingrezza
- Promising Future Prospects for Neurocrine: Buy Rating Affirmed by Analyst Marc Goodman